Skip to content

Restricted Cash at other companies

Merck & Co. logo
Merck & Co.MRK
$71M-31.1%
UroGen Pharma logo
UroGen PharmaURGN
$1.33M+23.3%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$1.28M+59.1%
Immunome logo
ImmunomeIMNM
$210K+110%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$3M0.0%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Operating income-$34.9M-20.1%
Net income-$33.7M-22.6%
EPS (diluted)-$0.50+9.1%

Balance sheet

See full
Cash & equivalents$84.8M+122%
Total debt$17.0M-7.9%
Total equity$107.2M-16.2%
Total assets$137.7M-11.4%

Cash flow

See full
Operating cash flow-$29.9M-28.0%
CapEx$102.0K-45.5%
Free cash flow-$30.0M-27.4%

Valuation

See full
Market cap$709.23M+89.4%
Enterprise value$641.43M+80.8%

Returns & leverage

See full
Return on equity-95.6%+222pp
Debt / equity0.2×0.0×
Current ratio7.1×-4.0×

Where this comes from

Reported directly by Aura Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalentsNoncurrent.

The official record: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aura Biosciences, Inc.'s restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aura Biosciences, Inc.'s restricted cash?
Aura Biosciences, Inc. (AURA) reported restricted cash of $768K in Q1 2026.
How has Aura Biosciences, Inc.'s restricted cash changed year-over-year?
Aura Biosciences, Inc.'s restricted cash decreased by 0.0% year-over-year, from $768K to $768K.
What is the long-term trend for Aura Biosciences, Inc.'s restricted cash?
Over 5 years (2020 to 2025), Aura Biosciences, Inc.'s restricted cash has grown at a 109.6% compound annual growth rate (CAGR), from $19K to $768K.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.